Rocking Pneumonia and the Boogie Woogie Flu

Authors:	*Ger Rijkers, Sophie Croon, Thuc Anh Nguyen
	Science Department, University College Roosevelt, Middelburg, Netherlands
	*Correspondence to g.rijkers@ucr.nl

Abstract

The relation between pneumonia and influenza is regularly addressed in modern music. Epidemiological data obtained during influenza pandemics, as well as during seasonal influenza, illustrate and underscore this association. Even though the number of pneumonia cases are generally under-reported and blood tests show a lack of sensitivity, a clear link between influenza and pneumonia can still be observed. In fact, the majority of mortality during influenza pandemics is due to pneumonia caused by a bacterial superinfection, in most cases *Streptococcus pneumoniae*. Vaccination is a powerful tool to prevent the development of both influenza and pneumonia in children, as well as in the elderly. Cellular and molecular data show that influenza can lead to changes in the integrity of lung epithelial cells, including desialysation of carbohydrate moieties, which favour attachment and invasion of *S. pneumoniae*. Further elucidation of these mechanisms could lead to targeted intervention strategies, in which universal influenza vaccines could play a role.

INTRODUCTION

The epidemiological association between influenza and pneumonia is well known. In this paper, the authors review the cellular and molecular mechanisms that underlie this association.

The association between influenza and pneumonia is also well known to the general public, as reflected in pop culture. Previously, the authors have analysed the context in which pneumonia (the disease) is dealt with in rock songs.[1] One of the findings was that most songwriters and singers have little idea about the infectious nature of pneumonia.[2] Taking into account that the causes of pneumonia, as well as its symptoms, treatment, and prognosis, are poorly described in songs, it is remarkable that the association between pneumonia and influenza is rather adequately depicted in music.[1] The best example may be from Huey 'Piano' Smith: "Young man rhythm's got a hold of me too, I got the rockin' pneumonia and the boogie woogie flu," from the 1957 record "Rockin' Pneumonia and the Boogie Woogie Flu". Followed later in 1960, The Genies released their song "Twisting Pneumonia": "I've got the twistin' pneumonia, the shimmy shimmy flu, the doctor is gonna tell you that there ain't no cure." Because the relationship between fantasy forms of pneumonia (rockin', twistin') and fantasy forms of influenza (boogie woogie, shimmy shimmy) is so evidently described in music, the epidemiological and molecular mechanisms underlying this relation warrant closer analysis. Hopefully this will lead to a moment in time when 'the doctor is gonna tell you that there *is* a cure'.

THE EPIDEMIOLOGICAL ASSOCIATION BETWEEN INFLUENZA AND PNEUMONI

In the 20th century, the world experienced three major influenza pandemics. Namely, the Spanish influenza in 1918 (H1N1), Asian influenza in 1957 (H2N2), and Hong Kong influenza in 1968 (H3N2). The 1918 pandemic had an especially large impact, with conservative estimates of 40–50 million deaths following H1N1 infection.[3] Many studies have shown that bacterial superinfection causing pneumonia following an influenza infection leads to severe disease and mortality. It has been estimated that >95% of deaths during the 1918 pandemic were complicated by bacterial pneumonia, most commonly by *Streptococcus pneumoniae*.[4] However, other common respiratory pathogens, including *Staphylococcus aureus, Haemophilus influenzae,* and *Streptococcus pyogenes* were all identified as predominant pathogens in various individual studies.[5] It has been predicted that due to the ever-increasing world population and global mobility, both work related and recreational, a future influenza outbreak with a strain with similar virulence to the 1918 Spanish influenza strain may cause even higher mortality rates, with an estimate of between 50 and 80 million deaths.[6] Such an outbreak would primarily affect developing countries, because of the limited preparedness and availability of healthcare facilities. Additionally, an epidemiological risk factor is the higher carriage rates of *S. pneumoniae* among children, as well as adults, in combination with limited availability of pneumococcal conjugate vaccine and antibiotics.[7] Generally, people living in sub-Saharan countries experience the highest rates of influenza-associated respiratory deaths, whereas eastern Mediterranean and southeast Asian countries have lower, but still high, death rates.[8,9] These findings underline the importance of understanding the synergy and copathogenesis between influenza and subsequent infection by bacterial pathogens, leading to bacterial pneumonia.

An influenza outbreak does not have to be a pandemic to cause substantial mortality. Annual seasonal influenza episodes are associated with significant morbidity. The Centre for Disease Control and Prevention (CDC) estimates that there are between 3 and 5 million annual cases of severe illness due to influenza, and between 291,000 and 646,000 deaths that are a direct consequence of seasonal influenza-related respiratory illnesses.[9] Children and the elderly are especially susceptible, particularly those who are <4 years and >65 years of age. Children <1 year of age account for >50% of all influenza-associated deaths in young children.[10] Influenza numbers reach their peak during the winter months. The incidence is highest during this time of year because the aerosol spread of the influenza virus depends on both the humidity and temperature of the air. Both cold and dry conditions favour transmission; thus,[11] the environmental conditions favouring influenza transmission are relatively well known.[12-14] For *S. pneumoniae,* the transmission mechanisms are known but not the environmental conditions.

Seasonal outbreaks of influenza, rather than pandemics, also are associated with a higher incidence of pneumonia. In the Netherlands, a clear rise in pneumonia can be observed during the peak of the influenza season (Figure 1).[15] However, influenza-related pneumonia is most likely highly under-reported, because in cases of community-acquired pneumonia there is often no culture made of the disease-inducing bacterium. Furthermore, blood cultures in patients with pneumonia lack sensitivity, providing accurate results in only 10–15% of cases. However, even when including sputum cultures, urinary tests, and serotype specific antibodies responses, the aetiological agent responsible for community acquired pneumonia often cannot be established.[16-18]

Pneumonia poses a significant risk for morbidity and mortality in young children as well as the elderly. In 2008, approximately 156 million children worldwide were affected by pneumonia, with an approximate 1.3 million deaths, accounting for 18% of all deaths of children <5 years old.[19,20] Furthermore, in people >65 years of age, 40% of pneumonia cases are of a severity that requires hospital admission.[21]

Vaccination is a primary strategy to reduce the burden imposed by influenza. Currently, the CDC recommends the annual influenza vaccine for everyone ≥6 months of age.[9] Live-attenuated influenza vaccines were shown to be most effective in those between 6 months and 7 years of age.[22]

Figure 1: Seasonal trends in incidence of influenza-like illness (blue line) and pneumonia (orange line) as reported by general practitioners in the Netherlands during the 2017-18 winter season.

Data derived from the public available weekly surveillance reports published by NIVEL.[15]

The influenza vaccine's efficacy is 56% (95% confidence interval [CI]: 39–68%) for preventing respiratory illness, 53% (CI: 35–66%) for preventing pneumonia, 50% (CI: 28–65%) for preventing hospitalisation, and 68% (CI: 56–76%) for preventing death.[23] Seasonal influenza vaccination thus shows efficacy in reducing pneumonia morbidity and mortality.

Following the introduction of pneumococcal conjugate vaccination of children in the USA and elsewhere, the incidence of clinically diagnosed all-cause pneumonia declined by 39% (95% CI: 22–52%).[24] Additionally, pneumococcal conjugate vaccines have played an important role in reducing influenza-associated morbidity,

preventing 31% (95% CI: 15–43%) of pneumonia cases associated with any of seven respiratory viruses in hospitalised children.[25] It was also shown that the children that received the vaccine and subsequently developed laboratory-confirmed influenza were at a 45% lower risk (95% CI: 14–64%) of hospitalisation due to the influenza-associated pneumonia.[26] It would be highly unlikely that vaccination with pneumococcal conjugate vaccines (composed of pneumococcal polysaccharides conjugated to bacterial carrier proteins) would have a direct protective effect against infection with respiratory viruses. Therefore, the interpretation of these data would be that recipients infected with respiratory viruses had a lower subsequent

complication rate of pneumococcal infection, due to serotype-specific protection. These children, protected against superimposed pneumococcal pneumonia developing due to the viral (influenza) infection, were less likely to progress to pneumonia requiring hospitalisation.[27]

In elderly people, influenza vaccination lowers the risk of laboratory-confirmed influenza.[28] Additional research in immunocompetent individuals aged ≥65 years examined the effects of influenza and pneumococcal vaccination in the prevention of hospital admissions. The influenza vaccine has an efficacy of 30% (95% CI: 17–42%) for high-risk and a 40% (95% CI: 1–64%) efficacy for median-risk elderly persons in preventing influenza and pneumonia hospitalisations and that the pneumococcal vaccine has a 75% (95% CI: 57–85%) efficacy in preventing invasive pneumococcal disease in people >65 years of age.[29,30] These studies suggest that the vaccination of both infants and the elderly may greatly reduce influenza-related morbidity and, combined with the data on herd immunity, suggest that immunisation of children may additionally protect adults as well.[26] This has been demonstrated both for influenza[31] as well as pneumococcal vaccination;[32] in both instances, childhood vaccination had an indirect protective effect on the elderly.

CELLULAR AND MOLECULAR MECHANISMS UNDERLYING THE INTERACTION BETWEEN INFLUENZA AND PNEUMONIA

As indicated and discussed above, during and after the influenza pandemic in 1918, the association of a respiratory virus predisposing to a bacterial infection was already recognised.[33] Multiple mechanisms could explain this association between influenza and pneumococcal infections, including impairment of host immune responsiveness, exacerbation of inflammatory mediators, and biofilm dispersion. The influenza A virus impairs both the host's innate and adaptive immune systems by downregulating IFN-γ production and by other means.[34] Infection with influenza H1N1 leads to a decrease in CD4+ T lymphocytes and B lymphocytes.[35] Furthermore, viral infections of the airways can induce a 'cytokine storm' and the

production of various other mediators, including histamine and leukotriene E4, that damage local lung tissue indirectly;[36-38] thus, influenza infected patients would become more susceptible to diseases such as pneumonia. In the nasopharynx of patients already colonised, *pneumococci* have formed biofilms. Influenza virus infection can trigger biofilm dispersion and active release of *pneumococci*.[39] It has been observed, both *in vitro* and *in vivo*, that during influenza infection, pneumococcal colonisation of respiratory epithelial surfaces can increase. *In vitro* data indicate that desialylation of airway epithelial cells, which occurs during influenza virus infection, can enhance pneumococcal adhesion via galectin binding.[40] Influenza-virus-infected mice failed to kill *S. pneumoniae in vivo*.[41] Additionally, similar relationships have been demonstrated in other viral respiratory viruses and bacteria that can cause pneumonia in humans. One of the first studies in that respect was conducted by Sanford et al.[42] by means of an adherence assay. In this experiment, group B *Streptococcus* and several other streptococcal species were found colonising only on the cells infected with influenza virus. A more recent study showed that cells infected with swine influenza virus have enhanced bacterial adherence and invasion of deeper tissues of *Streptococcus suis*,[43] a bacterium that can also cause pneumonia in humans.[44] Evidence has shown that viruses might promote bacterial infection by facilitating the colonisation, adherence, and translocation of bacteria through the epithelium. There are a number of mechanisms determining these processes, which involve changes and damage to host epithelial cells, several specific viral virulence determinants, and extracellular molecules, which are detailed below.

Viruses Damage Host Respiratory Epithelial Cells Facilitating Bacterial Adhesion

Infection with influenza virus results in multiple changes in the lung epithelial cells. Upon infection, inflammatory reactions are initiated, aiming to neutralise the virus but at the same time inevitably resulting in damage to the epithelial cells that mediate respiratory gas exchange. As the respiratory mucosa (the physical and chemical barrier to infection by producing

mucus, surfactants, and other inflammatory mediators) is damaged, opportunistic bacteria, such as *S. pneumoniae,* can more easily invade and colonise the lung tissue.[45] The deposition of dead cells and cell fragments into the airways also provides a rich source of nutrients for bacterial growth.[46] Furthermore, cilia are damaged and ciliary motion becomes unco-ordinated, causing impairment of their cleaning function.[47] Both the respiratory epithelial damage and impairment in protective mechanism caused by (influenza) viruses facilitates the adherence of bacteria to host cells. Evidence for this mechanism was reported in pathologic examination of patients who died of community acquired *S. aureus* pneumonia in the 1957 influenza pandemic. Autopsies showed that *Staphylococci* were adhered in regions of the tracheobronchial tree where the epithelial layer had been destroyed and sloughed off.[48] However, most seasonal influenza strains do not result in severe lung damage but can still facilitate bacterial superinfection.[49]

VIRULENCE DETERMINANTS OF INFLUENZA INCREASE RECEPTOR AVAILABILITY FOR BACTERIA

While viruses expose sites for attachment as previously outlined, bacteria also possess a wide range of virulence factors, such as pneumococcal surface protein A, choline-binding protein A, and pneumococcal serine-rich repeat protein.[50] These factors can be used for adherence to the basement membrane or extracellular matrix constituents of the host, such as fibrin, fibrinogen, and collagen.[51] *S. pneumoniae* illustrates this point clearly, as it was found to bind strongly to fibronectin. Viral infection also upregulates expression of fibronectin. Bacterial binding was thus enhanced proportionally to the increase of fibronectin and duration of exposure.[52] Moreover, influenza viruses can increase viral fitness and cytotoxic potential by antigenic variation and mutations, thus enhancing epithelial damage and subsequently facilitating bacterial infection.[53,54]

In addition to changing their antigenic surface, influenza infection can increase receptor availability for bacterial adherence and infection through three other mechanisms. First, influenza viruses insert their glycoproteins, neuraminidase and haemagglutinin, into the host membrane,

which subsequently acts as a potential receptor for bacteria.[55] Furthermore, viral neuraminidase cleaves sialic acid residues, including the sialic that cover bacterial receptors on cell surface carbohydrates, thus promoting bacterial adherence and invasion.[56] Indeed, it was found that treatment with neuraminidase inhibitor (oseltamivir) was associated with a reduction in mortality of at-risk patients diagnosed with the influenza A H1N1pdm09 virus infection.[57] In fact, this type of treatment was also widely used during the 2009–2010 influenza A H1N1 pandemic. However, neuraminidase and haemagglutinin inhibitors only inhibit streptococcal adherence to influenza-infected cells, not of *Staphylococci*, suggesting the presence of other cellular receptors for bacteria.

A second mechanism shows how viral infections can contribute to bacterial superinfection. The virus triggers a host inflammatory response, altering the cell membrane, and thus contributes to bacterial adherence. Influenza virus infection upregulated platelet activating factor receptor expression in lung epithelia, which promotes adhesion of *S. pneumoniae.*[58] Other respiratory viruses, such as respiratory syncytial virus, upregulate receptors that bacteria can bind to, such as CD14, CD15, and CD18, and receptors mediated by outer membrane protein P5 homologous fimbriae.[59,60] It is interesting to note that cigarette smoke and e-cigarette vapour both increase the expression of platelet activating factor receptor.[61,62]

A third and final mechanism, more general in nature, is that areas of incomplete wound healing (induced by influenza or otherwise) might be avid binding sites for bacteria. Fibrinogen expression is increased in incomplete wound healing.[62] The surface adhesin PfbA of *S. pneumoniae* binds to fibrinogen.[64] Furthermore, bacteria, including *S. pneumoniae,* can also adhere to extracellular matrix components involved in tissue repair, including laminin and type I and type IV collagen.[5]

CONCLUSION

The authors have elaborated on the special interaction between (a rocking, or whatever cause) pneumonia and the (boogie woogie) flu. There are arguments to propose that other respiratory viruses can pave the airways for bacterial pneumonia.[25,27] As indicated above,

in a substantial number of patients with community-acquired pneumonia, a causative agent has not been found, so these could also be pneumococcal pneumonia.[17,18] In cases where influenza virus, or any other respiratory virus for that matter, is found, it can be debated whether this infection would be sufficient argument for the classification of viral pneumonia.

The interaction between influenza, other respiratory viruses, and *S. pneumoniae* is complex and based on multiple mechanisms. Full understanding of these mechanisms, as well as their mutual interplay, is relevant for a better estimation of the burden of pneumonia in young children. Nasopharyngeal carriage with *pneumococci* is high during the first 3–5 years of age;[65,66] mucosal pneumococcal infections, such as otitis media, are prevalent during this period. Fortunately, most children do not develop a pneumococcal pneumonia. The triggering event for this development could be influenza infection. From such a perspective, it could be speculated that universal influenza vaccines could offer the broadest possible coverage against pneumococcal pneumonia in young children.[67,68] The moment these vaccines become available, clinical studies should include their effect on pneumococcal pneumonia.

References

1. Rijkers GT, Rodriguez Gomez M. Rocking pneumonia. Pneumonia (Nathan). 2017;9:18.

2. Bacharach B, Anyone who had a heart – The art of the songwriter (2013), New York: Harper.

3. Potter CW, "Chronicle of influenza pandemics," Nicholson KG et al. (eds.), Textbook of influenza (1998), London: Blackwell Scientific Publications, pp.3-18.

4. Morens DM et al. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-70.

5. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nature Rev Microbiol. 2014;12(4):252-62.

6. Murray CJ et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: A quantitative analysis. Lancet. 2006;368(9554):2211-8.

7. Chien YW et al. Bacterial pathogens and death during the 1918 influenza pandemic. New Engl J Med. 2009;361(26):2582-3.

8. Katz MA et al. Influenza in Africa: Uncovering the epidemiology of a long-overlooked disease. J Infect Dis. 2012;206 Suppl 1:S1-4.

9. CDC Newsroom. Seasonal flu death estimate increases worldwide. 2017. Available at: https://www.cdc.gov/media/releases/2017/p1213-flu-death-estimate.html. Last accessed: 2 June 2018.

10. Neuzil KM et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. New Engl J Med. 2000;342(4):225-31.

11. Lowen AC et al. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007;3(10):1470-6.

12. Pica N, Bouvier NM. Environmental factors affecting the transmission of respiratory viruses. Curr Opin Virol. 2012;2(1):90-5.

13. Ng S, Gordon A. Influenza burden and transmission in the tropics. Curr Epidemiol Rep. 2015;2(2):89-100.

14. Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88(14):7692-5.

15. NIVEL. Available at: https://www.nivel.nl. Last accessed: 2 June 2018.

16. Madhi SA et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and-uninfected children. Clin Infect Dis. 2005;40(10):1511-8.

17. van Mens SP et al. Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone. Clin Vaccine Immunol. 2011;18(5):796-801.

18. Rijkers GT et al. Triptych of the hermit saints: Pneumococcal polysaccharide vaccines for the elderly. Risk Manag Healthcare Policy. 2018;11:55-65.

19. Ruuskanen O et al. Viral pneumonia. Lancet. 2011;377(9773):1264-75.

20. Liu L et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151-61.

21. Jackson ML et al. The burden of community-acquired pneumonia in seniors: Results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50.

22. Osterholm MT et al. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.

23. Gross PA et al. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature. Annals Intern Med. 1995;123(7):518-27.

24. Grijalva CG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet. 2007;369(9568):1179-86.

25. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature Medicine. 2004;10(8):811.

26. Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science. 2007;316(5821):49-50.

27. Madhi SA et al. Interaction between influenza virus and Streptococcus pneumoniae in severe pneumonia. Expert Rev Resp Med. 2008;2(5):663-72.

28. Govaert TM et al. The efficacy of influenza vaccination in elderly individuals: A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661-5.

29. Mullooly JP et al. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization. Annals Intern Med. 1994;121(12):947-52.

30. Butler JC et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA. 1993;270(15):1826-31.

31. Cohen SA et al. Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006. J Am Geriatr Soc. 2011;59(2):327-32.

32. Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine. 2017;35(22):2882-91.

33. Lai SH et al. Preceding human metapneumovirus infection increases adherence of Streptococcus pneumoniae and severity of murine pneumococcal pneumonia. J Microbiol Immunol Infect. 2016;49(2):216-24.

34. Chen X et al. Host immune response to influenza A virus infection. Front Immunol. 2018;9:320.

35. Giamarellos-Bourboulis EJ. Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One. 2009;4(12):e8393.

36. Busse WW et al. Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol. 1983;71(4):382-8.

37. Chonmaitree T et al. Role of interferon in leukocyte histamine release caused by common respiratory viruses. J Infec Dis. 1988;157(1):127-32.

38. Yasuda H et al. Inflammatory and bronchospastic factors in asthma exacerbations caused by upper respiratory tract infections. Tohoku J Exp Med. 2005;207(2):109-18.

39. Chao Y et al. Streptococcus pneumoniae biofilm formation and dispersion during colonization and disease. Front Cell Infect Microbiol. 2014;4:194.

40. Nita-Lazar M et al. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Mol Immunol. 2015;65(1):1-16.

41. LeVine AM et al. Decreased pulmonary clearance of Streptococcus pneumoniae following influenza A infection in mice. J Virol Methods. 2001;94(1-2):173-86.

42. Sanford BA et al. Bacterial adherence to virus-infected cells: A cell culture model of bacterial superinfection. J Infect Dis. 1978;137(2):176-81.

43. Meng F et al. Dynamic virus-bacterium interactions in a porcine precision-cut lung slice coinfection model: Swine influenza virus paves the way for Streptococcus suis infection in a two-step process. Infect Immun. 2015;83(7):2806-15.

44. Huong et al. Epidemiology, clinical manifestations, and outcomes of Streptococcus suis infection in humans. Emerg Infect Dis. 2014;20(7):1105-14.

45. Sanders CJ et al. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res. 2011;343(1):13-21.

46. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nature Rev Microbiol. 2014;12(4)252-62.

47. Levandowski RA et al. Modifications of lung clearance mechanisms by acute influenza A infection. J Lab Clin Med. 1985;106(4):428-32.

48. Hers JF et al. Bacteriology and histopathology of the respiratory tract and lungs of fatal Asian influenza. Lancet. 1958;2(7057):1141-3.

49. Guarner J et al. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res. 2009;40(8):655-61.

50. McCullers JA, Tuomanen EI. Molecular pathogenesis of pneumococcal pneumonia. Front Biosci. 2001;6:D877-89.

51. Dockrell DH et al. Pneumococcal pneumonia: Mechanisms of infection and resolution. Chest. 2012;142(2):482-91.

52. van der Flier M et al. Adherence of streptococcus pneumoniae to immobilized fibronectin. Infect Immun. 1995;63(11):4317-22.

53. Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci. 2014;1323:115-39.

54. Nguyen TA et al. The martyrdom of St. Julia: On microbial strategies to evade the immune system. Asian J Immunol. 2018;1(1):1-13.

55. Hament JM et al. Respiratory viral infection predisposing for bacterial disease: A concise review. FEMS Immunol Med Microbiol. 1999;26(3-4):189-95.

56. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: Role of neuraminidase. Pediatr Infect Dis J. 2004;23(1 Suppl):S87-97.

57. Muthuri SG et al.; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404.

58. van der Sluijs KF et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L194-9.

59. Miller ML et al. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis. 2007;195(4):581-4.

60. Raza MW et al. Infection with respiratory syncytial virus enhances expression of native receptors for non-pilate Neisseria meningitidis on HEp-2 cells. FEMS Immunol Med Microbiol. 1999;23(2):115-24.

61. Shukla SD et al. An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke. Int J Chron Obstruct Pulmon Dis. 2016;11:1647-55.

62. Miyashita L et al. E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells. Eur Respir J. 2018;51(2).

63. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153-62.

64. Radhakrishnan D. Streptococcus pneumoniae surface adhesin PfbA and its interaction with erythrocytes and hemoglobin. Int J Biol Macromol. 2018;120(Pt A):135-43.

65. Bogaert D et al. Pneumococcal carriage in children in the Netherlands: A molecular epidemiological study. J Clin Microbiol. 2001;39(9):3316-20.

66. Devine VT et al. Nasopharyngeal bacterial carriage in the conjugate vaccine era with a focus on Pneumococci. J Immunol Res. 2015;2015:394368.

67. The Lancet Infectious Diseases. Plotting a route to a universal influenza vaccine. Lancet Infect Dis. 2018;18(5):475.

68. Graul AI et al. The year's new drugs and biologics, 2017, part II - News that shaped the industry in 2017. Drugs Today (Barc). 2018;54(2):137-67.